December 20, 2017 08:21 AM EST

A US senator calls out a little biotech for price gouging. But will it change anything?

John Carroll

Editor & Founder

A little known biotech called Strongbridge Biopharma has attracted the attention of a prominent US senator who would like to make the company the latest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A US senator calls out a little biotech for price gouging. But will it change anything?

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Small personalized vaccine trial sees progress in late-stage kidney cancer

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

A US sen­a­tor calls out a lit­tle biotech for price goug­ing. But will it change any­thing?

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

A US senator calls out a little biotech for price gouging. But will it change anything?